China Interventional Cardiovascular Device Industry Report, 2013-2015 - Fox29 WFLX TV, West Palm Beach, Florida-

China Interventional Cardiovascular Device Industry Report, 2013-2015

Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact pressreleases@worldnow.com.

SOURCE ReportBuyer

LONDON, Feb. 13, 2014 PRNewswire/ -- Reportbuyer.com just published a new market research report:

China Interventional Cardiovascular Device Industry Report, 2013-2015

With the accelerated aging, the prevalence of cardiovascular diseases in China increased year by year. According to statistics of National Health and Family Planning Commission of the People's Republic of China, in 2012 cardiovascular disease deaths in China reached 3.5 million. The fast growing number of heart patients stimulated rapid growth in Chinese demand for interventional cardiac operation and coronary stent. China's PCI (percutaneous coronary intervention) surgeries increased from 25,000 cases in 2002 to about 531,000 cases in 2012; the number of coronary stent implantation rose from 40,000 units in 2002 to approximately 640,000 units in 2012. In 2007-2012 China's cardiovascular stent market size grew at an AAGR of 20.3%.

In China, interventional cardiovascular devices are dominated by cardiovascular stent. Currently, the top three companies in China's coronary stent market are respectively MicroPort, Lepu Medical and JW Medical; while supporting auxiliary devices such as catheter and guide wire feature low localization rate, mainly dependent on imports. In 2012, Chinese enterprises accounted for 66.8% of Chinese interventional cardiovascular device market share, followed by foreign counterparts with 33.2%.

Interventional cardiovascular device is a sunrise industry, there lies strong clinical demand for safer and more effective interventional products, and thus the world's major manufacturers have invested heavily in research and development of new products. Bioabsorbable everolimus-eluting stent (BVS) has become the focus of attention. Abbott in September 2012 launched the world's first A bioabsorbable everolimus-eluting coronary stent system (ABSORB), expected to bring a revolutionary change in coronary artery disease (CAD) treatment; MicroPort's third-generation completely biodegradable drug-eluting stent Firehawk has completed clinical trials in China; Lepu Medical's completely biodegradable drug-eluting stent is also in active research and development.

China Interventional Cardiovascular Device Industry Report, 2013-2015 mainly covers the followings:

Development, market demand, competition pattern, profit level, etc. of the industry;
Policy environment, impacts from upstream and downstream sectors, etc.;
Market size, supply and demand, product price, etc. of industry segments (including coronary stent, balloon catheter, guide wire, sheath group and auxiliary device), etc.;
Operation, interventional device cardiovascular business, operation in China, etc. of global companies (including Johnson & Johnson, Medtronic, Boston Scientific, Abbott Laboratories, B. Braun);
Operation, interventional cardiovascular device business, etc. of Chinese companies (including MicroPort, Lepu Medical, Lifetech Scientific, JW Medical, Liaoning Bio-medical Technology, OrbusNeich, SCW Medicath, Amtech Biotech and Starway Medical).
1. Overview of Interventional Cardiovascular Device Industry
1.1 Definition
1.2 Product Types and Applications
1.3 Industry Chain

2. Status Quo of China Interventional Cardiovascular Device Industry
2.1 Overview
2.2 Market Demand
2.3 Import and Export
2.4 Competition Pattern
2.5 Profit
2.6 Entry Barriers
2.6.1 Technology
2.6.2 Talent
2.6.3 Patent
2.6.4 Policy
2.6.5 Market Access

3. Development Environment for China Interventional Cardiovascular Device Industry
3.1 Policy Environment
3.1.1 Regulatory Policy
3.1.2 Industry Policy
3.2 Upstream and Downstream Sectors
3.2.1 Upstream
3.2.2 Downstream

4. Market Segments
4.1 Coronary Stent
4.1.1 Market Profile
4.1.2 Drug-Eluting Stent
4.1.3 Bare Metal Stent
4.1.4 Bioabsorbable Stent
4.2 Balloon Catheter
4.2.1 Market Profile
4.2.2 Supply and Demand
4.3 Catheter
4.3.1 Market Profile

4.3.2 Sales
4.4 Guide Wire
4.4.1 Market Profile
4.4.2 Sales
4.5 Sheath Group and Auxiliary Devices
4.5.1 Market Profile
4.5.2 Sales

5. Foreign Companies
5.1 Johnson & Johnson
5.1.1 Profile
5.1.2 Operation
5.1.3 Interventional Cardiovascular Device Business
5.1.4 Operation in China
5.2 Medtronic
5.2.1 Profile
5.2.2 Operation
5.2.3 Revenue Structure
5.2.4 Operation in China
5.3 Boston Scientific
5.3.1 Profile
5.3.2 Operation
5.3.3 Operation in China
5.4 Abbott Laboratories
5.4.1 Profile
5.4.2 Operation
5.4.3 Operation in China
5.5 B. Braun
5.5.1 Profile
5.5.2 Operation
5.5.3 Operation in China

6. Chinese Companies
6.1 MicroPort
6.1.1 Profile
6.1.2 Operation
6.1.3 Revenue Structure
6.1.4 Gross Margin
6.1.5 R&D and Investment
6.1.6 Interventional Cardiovascular Device Business
6.1.7 Forecast and Outlook
6.2 Lepu Medical
6.2.1 Profile
6.2.2 Operation
6.2.3 Revenue Structure
6.2.4 Gross Margin
6.2.5 R&D and Investment
6.2.6 Interventional Cardiovascular Device Business

6.2.7 Forecast and Outlook
6.3 Lifetech Scientific
6.3.1 Profile
6.3.2 Operation
6.3.3 Revenue Structure
6.3.4 Gross Margin
6.3.5 R&D and Investment
6.3.6 Interventional Cardiovascular Device Business
6.4 JW Medical
6.4.1 Profile
6.4.2 Operation
6.4.3 Development
6.5 Liaoning Bio-medical
6.5.1 Profile
6.5.2 Operation
6.5.3 Development
6.6 OrbusNeich
6.6.1 Profile
6.6.2 Operation
6.6.3 Development
6.7 Sinomed
6.7.1 Profile
6.7.2 Operation
6.7.3 Development
6.8 SCW Medicath
6.8.1 Profile
6.8.2 Operation
6.9 Amtech Biotech
6.9.1 Profile
6.9.2 Operation
6.10 Starway Medical

Companies Mentioned

Johnson & Johnson
Medtronic
Boston Scientific
Abbott Laboratories
B. Braun
MicroPort
Lepu Medical
Lifetech Scientific
JW Medical
Liaoning Bio-medical
OrbusNeich
Sinomed
SCW Medicath
Amtech Biotech
Starway Medical

Read the full report:
China Interventional Cardiovascular Device Industry Report, 2013-2015
http://www.reportbuyer.com/pharma_healthcare/medical_device_country_region/china_interventional_cardiovascular_device_industry_report.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Cardiovascular_Devices

For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: query@reportbuyer.com  
Tel: +44 208 816 85 48
Website: www.reportbuyer.com

©2012 PR Newswire. All Rights Reserved.

Powered by WorldNow

1100 Banyan Blvd.
West Palm Beach, FL 33401

FCC Public File
publicfile@wflx.com
561-282-5043
EEO Report
Closed Captioning

All content © Copyright 2000 - 2014 Worldnow and WFLX. All Rights Reserved.
For more information on this site, please read our Privacy Policy and Terms of Service.